Singapore, March 11 -- A newly released white paper, based on research conducted independently byIQVIA, a global healthcare consultancy, and commissioned by GSK, has highlighted the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV) on older adults aged 60 years or over in high-income Asia-Pacific Economic Cooperation (APEC) countriesand regions,includingAustralia,Hong Kong,Japan, andSingapore.

The white paper estimated that in 2023, RSV led to approximately 3,251 hospitalisations amongst older adults inSingaporeand is linked to a higher per-person direct medical cost (compared to cost inAustraliaandJapan) to cover inpatient stays, increased hospitalisation length, ICU resources, and emergency visits.

Amongst the ...